This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Astrazeneca (AZN) Loses -5.29% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
Astrazeneca (AZN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
AstraZeneca Inks Agreement to Boost Cardiovascular Pipeline
by Zacks Equity Research
AZN inks an agreement with CSPC Pharmaceutical to develop a novel lipid-lowering therapy targeting various cardiovascular diseases.
Zacks Industry Outlook Eli Lilly, AstraZeneca, Pfizer, Sanofi and Bayer
by Zacks Equity Research
Eli Lilly, AstraZeneca, Pfizer, Sanofi and Bayer have been highlighted in this Industry Outlook article.
ONCY Stock Up on Regulatory Update From Breast Cancer Program
by Zacks Equity Research
Oncolytics stock soars as the company seeks an accelerated approval pathway for its lead candidate, pelareorep, to treat a breast cancer indication.
5 Large Drug Stocks to Watch From a Thriving Industry
by Kinjel Shah
Drug and biotech companies are seeing significant innovation in 2024. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), AstraZeneca (AZN), Pfizer (PFE), Sanofi (SNY) and Bayer (BAYRY) are worth retaining in one's portfolio.
Pharma Stock Roundup: FDA Approves SNY's Dupixent for COPD & More
by Kinjel Shah
FDA approves Sanofi's Dupixent for COPD. Eli Lilly is set to invest $4.5 billion to build a new manufacturing and research site in Indiana.
AbbVie Cuts 2024 Earnings Guidance to Include Acquisition Costs
by Zacks Equity Research
ABBV lowers adjusted earnings guidance for 2024 from $10.71-$10.91 per share to $10.67-$10.87 to account for acquisition costs.
Eli Lilly to Invest $4.5B for New Manufacturing & Research Plant
by Zacks Equity Research
Lilly is investing $4.5 billion to build a new site for improving manufacturing and drug development.
AstraZeneca's Calquence sNDA Gets FDA Priority Tag for Expanded Use
by Zacks Equity Research
The FDA grants priority review to AZN's sNDA for Calquence for untreated mantle cell lymphoma. A decision is expected in first-quarter 2025.
Here's Why You Should Consider Buying Jazz Pharmaceuticals' Stock
by Zacks Equity Research
Here, we discuss some reasons why buying JAZZ stock now may turn out to be a prudent move.
AstraZeneca's Enhertu sBLA Gets FDA Priority Tag for Expanded Use
by Zacks Equity Research
The FDA grants priority review to AZN's sBLA for Enhertu to treat HER2-low or HER2-ultralow metastatic breast cancer. A decision is due in first-quarter 2025.
Is WisdomTree International Hedged Quality Dividend Growth ETF (IHDG) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for IHDG
Pharma Stock Roundup: JNJ's 3rd Talc-Related Bankruptcy Filing & More
by Kinjel Shah
JNJ files for voluntary bankruptcy for the third time. Pfizer withdraws sickle-cell drug drug Oxbryta from worldwide markets.
The Zacks Analyst Blog Highlights Toyota Motor, AstraZeneca, Chubb, Air T and Preformed Line Products
by Zacks Equity Research
Toyota Motor, AstraZeneca, Chubb, Air T and Preformed Line Products are part of the Zacks top Analyst Blog.
Top Stock Reports for Toyota, AstraZeneca & Chubb
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Toyota Motor Corp. (TM), AstraZeneca PLC (AZN) and Chubb Ltd. (CB), as well as two micro-cap stocks Air T, Inc. (AIRT) and Preformed Line Products Co. (PLPC).
AstraZeneca Stock Up Almost 14% in 6 Months: Time to Buy?
by Kinjel Shah
AZN's key drugs like Lynparza, Tagrisso, Imfinzi, Ultomiris and Farxiga are likely to drive sales. It has several candidates with blockbuster potential.
AZN's Tagrisso Gets FDA Nod for Expanded Use in NSCLC
by Zacks Equity Research
The FDA approves AstraZeneca's Tagrisso for treating unresectable, stage III EGFR-mutated non-small cell lung cancer.
Buy These 5 Big Drug Stocks to Boost Your Portfolio's Health
by Kinjel Shah
Pfizer, Eli Lilly, AstraZeneca, Bayer and Sanofi can prove to be great additions to your portfolio.
Biogen's Lupus Candidate Meets Key Goals in Phase III Study
by Zacks Equity Research
The phase III PHOENYCS GO study evaluating BIIB and UCB's drug candidate, dapirolizumab pegol, for treating systemic lupus erythematosus meets the primary endpoint.
Has Arbutus Biopharma (ABUS) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Arbutus Biopharma (ABUS) and Astrazeneca (AZN) have performed compared to their sector so far this year.
AZN Stock Slips as Dato-DXd Cancer Study Misses Survival Goal
by Zacks Equity Research
AZN's Daiichi Sankyo-partnered datopotamab deruxtecan fails to show overall survival benefits in a breast cancer study. Stock falls.
CHMP Endorses AstraZeneca's Fasenra in Rare Autoimmune Disease
by Zacks Equity Research
If approved, AZN's Fasenra will be the second biologic approved in the European Union to treat eosinophilic granulomatosis with polyangiitis.
EMA Committee Endorses AbbVie's Elahere in Ovarian Cancer
by Zacks Equity Research
If approved, this will be the first regulatory approval for ABBV's Elahere in the European Union.
Astrazeneca (AZN) Suffers a Larger Drop Than the General Market: Key Insights
by Zacks Equity Research
The latest trading day saw Astrazeneca (AZN) settling at $78.38, representing a -0.66% change from its previous close.
Pharma Stock Roundup: FDA Approvals for LLY, MRK, AZN & JNJ Drugs
by Kinjel Shah
FDA approves Lilly's eczema drug, Ebglyss, and the expanded use of Novartis' Kisqali, Merck's Keytruda and AstraZeneca's Fasenra.